Identifiability of PBPK models with applications to dimethylarsinic acid exposure Ramon I. GarciaJoseph G. IbrahimR. Woodrow Setzer Original Paper 21 July 2015 Pages: 591 - 609
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis Maria Luisa SarduItalo PoggesiGiuseppe De Nicolao Original Paper 26 July 2015 Pages: 611 - 626
A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times Jonathan KnightsShashank Rohatagi Original Paper 26 July 2015 Pages: 627 - 637
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics Thierry WendlingSwati DumitrasLeon Aarons Original Paper 01 August 2015 Pages: 639 - 657
Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities Eleonora MarosticaKarel Van AmmelAn Vermeulen Original Paper 11 August 2015 Pages: 659 - 679
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies Eric L. HaseltineHolly KimkoVarun Garg Original Paper 20 August 2015 Pages: 681 - 698
Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution Oskar CleweMats O. KarlssonUlrika S. H. Simonsson Original Paper Open access 28 August 2015 Pages: 699 - 708
Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice Wojciech KrzyzanskiJuan Jose Perez-RuixoJohn Harrold Original Paper 04 September 2015 Pages: 709 - 720
A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats Nieves Velez de MendizabalKimberley JacksonRobert R. Bies Original Paper 22 September 2015 Pages: 721 - 733
Inter occasion variability in individual optimal design Anders N. KristofferssonLena E. FribergJoakim Nyberg Original Paper Open access 01 October 2015 Pages: 735 - 750
